Ivermectin prescription rates in the USA have increased 70% this year, reaching 67,915 per month, according to an analysis by Komodo Health.
This analysis used Komodo’s Healthcare Map, a database of de-identified, real-world patient data tracking US patient journeys, to identify insurance claims for ivermectin and changes in claims rates across specialties.
The greatest increases in claims for ivermectin were seen in the states of Idaho, New Mexico, and Wyoming, with increases of 210%, 207%, and 201% respectively.
Prescriber specialties seem to imply off-label use for COVID-19, despite this not being recommended by regulators, with the research finding no increase in the prevalence of any disease that ivermectin is approved to treat.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze